Although LAG-3 blockade, along with IL-12 treatment, was shown to restore the anti-metastatic activity of NK cells in murine models of breast cancer, relatlimab did not directly induce NK cell-mediated cytotoxicity against leukemic cells. The gene discussed is LAG3; the disease is breast cancer.